The U.S. Department of Health and Human Services Office of Inspector General (HHS OIG) has informed a bipartisan group of House lawmakers that the enforcement agency does not plan to impose civil monetary penalties against the drug makers that have placed restrictions on 340B discounts in the contract pharmacy setting at this time, 340B Report has learned.
The decision occurs despite significant concern from hundreds of lawmakers from both parties who have been pushing HHS Secretary Xavier Becerra, HHS OIG Inspector General Christi Grimm and Health Resources and Services Administration Administrator Carole Johnson to take more aggressive steps against the drug companies. The latest Congressional request came just this week in a letter from Senators Joe Manchin (D-WV) and Mike Braun (R-Ind.) to HHS leadership.
The U.S Department of Health and Human Services Office of Inspector General (HHS OIG) has informed a bipartisan group of House lawmakers that the enforcement agency does not plan to impose civil monetary penalties against the drug makers that have placed restrictions or stopped providing 340B discounts in the contract pharmacy setting at this time, 340B Report has learned.
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.
